 |
 |
GEO help: Mouse over screen elements for information. |
|
Status |
Public on May 28, 2020 |
Title |
PRO-seq of THP-1 cells treated with LSD1 inhibitor INCB059872 |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing Other
|
Summary |
INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. We used precision nuclear run-on sequencing (PRO-seq) to define early transcriptional changes associated with INCB059872 treatment. Changes in nascent transcription could be traced back to a loss of CoREST activity resulting in activation of GFI1-regulated targets.
|
|
|
Overall design |
THP-1 cells were treated (in duplicate) with 25nM INCB059872 for 0, 6, 12, or 24hrs. PRO-seq was used to measure changes in nascent transcription.
|
|
|
Contributor(s) |
Johnston G, Hiebert S |
Citation(s) |
32422235 |
|
Submission date |
Feb 10, 2020 |
Last update date |
May 30, 2020 |
Contact name |
Scott Hiebert |
Organization name |
Vanderbilt University
|
Street address |
2220 Pierce Ave.
|
City |
Nashville |
State/province |
TN |
ZIP/Postal code |
37232 |
Country |
USA |
|
|
Platforms (1) |
GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
Samples (8)
|
|
Relations |
BioProject |
PRJNA605859 |
SRA |
SRP248057 |
Supplementary file |
Size |
Download |
File type/resource |
GSE145071_RAW.tar |
1.1 Gb |
(http)(custom) |
TAR (of BEDGRAPH) |
SRA Run Selector |
Raw data are available in SRA |
Processed data provided as supplementary file |
|
|
|
|
 |